4//SEC Filing
ROSSKAMP RALF 4
Accession 0000899243-19-030135
CIK 0001399529other
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 8:08 PM ET
Size
9.6 KB
Accession
0000899243-19-030135
Insider Transaction Report
Form 4
ROSSKAMP RALF
Chief Medical Officer
Transactions
- Sale
Common Stock
2019-12-26$22.69/sh−20,000$453,764→ 3,564 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-12-26−20,000→ 230,000 totalExercise: $2.91Exp: 2027-06-15→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2019-12-26$2.91/sh+20,000$58,200→ 23,564 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.48 to $23.13, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
- [F4]The option vested 25% on the first-year anniversary of the vesting start date of June 15, 2017 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.
Documents
Issuer
Dicerna Pharmaceuticals Inc
CIK 0001399529
Entity typeother
Related Parties
1- filerCIK 0001266625
Filing Metadata
- Form type
- 4
- Filed
- Dec 26, 7:00 PM ET
- Accepted
- Dec 27, 8:08 PM ET
- Size
- 9.6 KB